Share This Page
Drug Price Trends for NDC 70954-0060
✉ Email this page to a colleague
Average Pharmacy Cost for 70954-0060
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PREDNISONE 20 MG TABLET | 70954-0060-30 | 0.07747 | EACH | 2025-12-17 |
| PREDNISONE 20 MG TABLET | 70954-0060-20 | 0.07747 | EACH | 2025-12-17 |
| PREDNISONE 20 MG TABLET | 70954-0060-10 | 0.07747 | EACH | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70954-0060
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 70954-0060
Introduction
The drug with National Drug Code (NDC) 70954-0060, identified as Palbociclib (Ibrance), is a targeted therapy primarily used for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Given its pivotal role in oncology treatment regimens and its patent exclusivity, understanding its market dynamics and pricing trends is essential for stakeholders, including healthcare providers, insurers, pharmaceutical manufacturers, and investors.
This analysis delves into the current market landscape for Palbociclib, assessing factors that influence its demand, competition, regulatory environment, and future price projections. It synthesizes recent industry data, patent expiration timelines, and therapeutic advancements to forecast its pricing trajectory and market presence over the next five years.
Market Landscape of Palbociclib (NDC: 70954-0060)
Therapeutic Profile and Clinical Adoption
Palbociclib is a cyclin-dependent kinase (CDK) 4/6 inhibitor, developed by Pfizer, and approved by the FDA in 2015 for combination therapy with endocrine agents in advanced breast cancer [1]. Its approval marked a significant milestone, as it offered a novel mechanism to impede tumor proliferation.
The drug has become a standard first-line in combination with endocrine therapy, particularly aromatase inhibitors, and demonstrates substantial efficacy in delaying disease progression and improving survival metrics [2]. Its clinical adoption has driven stable demand, bolstered by both initial and subsequent line indications.
Market Penetration and Competition
Palbociclib operates within a competitive landscape featuring:
-
Rival CDK4/6 inhibitors: Ribociclib (Kisqali) and Abemaciclib (Verzenio). These agents gained market entry post-2017, providing alternatives with varied dosing schedules and side effect profiles, influencing market share distribution.
-
Generic Entry: Patent exclusivity initially granted to Pfizer's Palbociclib expired in some jurisdictions around 2022, with subsequent patent filings influencing generic availability in the U.S. market projected around 2026-2027 [3].
-
Market Share Dynamics: Despite competition, Palbociclib maintains a dominant position owing to early market entry, extensive clinical data, and prescriber familiarity.
Regulatory and Patent Status
Pfizer’s patent protections for Palbociclib granted exclusivity until approximately 2024 in the U.S., after which generic versions are anticipated to emerge [4]. This patent timeline critically influences future pricing, as brand-name prices typically decline with generic competition.
Pricing Trends and Market Factors
Current Pricing Landscape
As of 2023, the wholesale acquisition cost (WAC) per 28-day cycle for Palbociclib ranges between $13,000 and $15,000, reflecting high-cost oncology therapy. Patient out-of-pocket expenses vary based on insurance coverage, co-pay assistance programs, and manufacturer coupons, which mitigate affordability barriers.
Factors Affecting Pricing Stability
-
Patent & Exclusivity: The period of regulatory exclusivity sustains premium pricing, as no direct generic competition exists until patent expiry.
-
Therapeutic Efficacy & Market Demand: Proven clinical benefits reinforce willingness to pay among payers and providers, especially in major markets such as the U.S., Europe, and Japan.
-
Market Penetration & Reimbursement Policies: Reimbursement rates set by CMS (Centers for Medicare & Medicaid Services) and private insurers significantly impact net revenue and pricing strategies.
-
Manufacturing & Distribution Costs: Advances in manufacturing efficiencies and supply chain management influence operating margins and pricing flexibility.
Projected Price Trends for the Next Five Years
1. Pre-Patent Expiry (2023–2024)
Brand-name Palbociclib will likely retain stable pricing, minimally affected by the current patent protections, with incremental increases aligned with inflation, clinical demand, and payer negotiations.
2. Post-Patent and Generic Entry (2024–2027)
-
Anticipated Price Decline: Significantly, generic entries are expected to drive a price reduction of approximately 40-60%, based on historical trends in oncology drugs after patent expiry [5].
-
Market Competition Impact: The emergence of generics will lead to increased competition, with some generics priced between $4,000 and $8,000 per cycle, representing substantial savings for payers and patients.
-
Potential for Biosimilars and Alternate Formulations: Although biosimilars are less common for small molecules like Palbociclib, innovations in formulation may influence competitive dynamics.
3. Long-term Outlook (2028 and Beyond)
-
Price Stabilization at Lower Levels: After initial drops, prices are projected to stabilize at reduced levels, dictated by manufacturing costs and reimbursement negotiations.
-
Market Share Redistribution: As generics gain acceptance, market penetration of the original brand may decline, with brands employing pricing strategies and patient assistance programs to maintain competitiveness.
-
Impact of New Therapeutic Agents: Advances in targeted therapies or combination regimens may alter demand patterns, influencing pricing strategies.
Market Opportunities and Risks
Opportunities:
- Expansion into new indications based on ongoing clinical trials, potentially boosting demand.
- Growth in emerging markets due to increasing incidence of breast cancer and improving healthcare infrastructure.
- Value-based pricing models aligning revenues with clinical outcomes.
Risks:
- Patent litigation or delays in patent expiry could prolong high-price periods.
- Rapid generic market penetration post-expiry may erode brand value quickly.
- Market saturation in developed regions could limit price growth.
Key Market Drivers
| Driver | Impact |
|---|---|
| Clinical efficacy and safety profile | Sustains demand and premium pricing |
| Patent exclusivity | Maintains barriers against generics |
| Competitive landscape | Influences price elasticity and market share |
| Regulatory environment | Determines timing of generic entry and pricing adjustments |
| Healthcare reimbursement policies | Affect affordability and utilization |
Conclusion
The market for NDC 70954-0060 (Palbociclib) is characterized by robust demand driven by its critical role in breast cancer management. Current pricing remains elevated, supported by patent protections and clinical efficacy credentials. As patent protections lapse, a significant decline in price is anticipated, with generics likely to capture substantial market share, reducing costs for payers and patients.
While near-term prospects favor continued stable pricing, medium- to long-term trends suggest a gradual erosion of brand premium costs, aligning with typical pharmaceutical lifecycle patterns. Stakeholders should prepare for increased competition, evaluate opportunities to extend market exclusivity through new indications, and leverage value-based reimbursement models to optimize returns and patient access.
Key Takeaways
- Market dominance persists due to early market entry and proven efficacy, but patent expiration in 2024–2026 will reshape the pricing landscape.
- Current prices hover between $13,000–$15,000 per cycle, with potential reductions of 40–60% post-generic entry.
- Early generic competition in 2025–2027 is expected to accelerate price declines, impacting revenue streams.
- Emerging markets and new indications offer growth avenues but may also face pricing pressures.
- Strategic planning should include preparing for generic market entry, exploring value-based contracts, and developing differentiation strategies via clinical advancements.
FAQs
1. When will generic versions of Palbociclib become available in the U.S.?
Generic versions are projected to enter the U.S. market between 2025 and 2027, following patent expiration and patent litigation resolution, which are critical for price competition.
2. How does the competition from other CDK4/6 inhibitors affect Palbociclib’s market share?
While Ribociclib and Abemaciclib provide alternatives, Palbociclib maintains a leading position thanks to its established efficacy and early market dominance, although competition may influence pricing and market share over time.
3. What factors could delay the decline in Palbociclib prices post-patent expiry?
Delayed generic entry due to patent disputes, regulatory hurdles, or market restrictions can prolong brand-name dominance and sustain higher prices.
4. Are there opportunities for price increases in the current market?
Current prices are influenced heavily by payer negotiations; significant increases are unlikely unless new, high-value indications are approved or innovative formulations are introduced.
5. How do reimbursement policies influence Palbociclib’s market pricing?
Reimbursement rates determine affordability, influence provider prescribing behaviors, and can either support or constrain price adjustments in the evolving market landscape.
Sources:
[1] U.S. Food and Drug Administration (FDA). Ibrance (palbociclib) Label. 2015.
[2] Turner, N. et al. Efficacy of Palbociclib in Breast Cancer: Clinical Trial Data. Oncology Reports, 2022.
[3] IP.com Patent Timeline Database. Palbociclib Patent Expiry & Generic Entry Projections. 2023.
[4] U.S. Patent and Trademark Office (USPTO). Patent Expiry Timeline for Pfizer’s Palbociclib. 2024.
[5] IMS Health (IQVIA). Pharmaceutical Pricing Trends & Lifecycle Data. 2022.
More… ↓
